This examination analyzed between oral cabergoline and rectal bromocriptine in the treatment of female patients experiencing. This investigation was directed on 220 female patients experiencing hyperprolactinemia with whose serum prolactin level over 25 ng/ml. A definite history taking, clinical assessment and serum prolactin level were done to all members. patients were isolated into two gatherings in a randomized example; gathering (a), included 110 patients were treated with 2.5 mg bromocriptine rectally day by day once as long as 3 months.; gathering (b), included 110 patients were treated with oral cabergoline.1/2 tablet two times per week as long as 3 months. Prolactin level was tested before treatment then following a month and 4 months individually, contrasting prolactin level pre-and post-treatment, there was huge abatement in prolactin level after treatment in Bromocriptine gathering (mean prolactin= 16.5 versus 40, p < 0.001); just as in Cabergoline gathering (mean prolactin= 11.3 versus 41, p < 0.001). Cabergoline bunch after treatment had altogether lower prolactin level when contrasted with Bromocriptine gathering (p < 0.001). Change in prolactin level after treatment contrasting with pattern level was determined, Cabergoline bunch demonstrated essentially higher rate change in prolactin level when contrasted with Bromocriptine gathering (mean rate change=64.9% versus 55%, p < 0.001). Delineating cases into intermittent and non-repetitive hyperprolactinemia, uncovered that those with non-repetitive hyperprolactinemia, cabergoline bunch had fundamentally lower level when contrasted with bromocriptine gathering (11.3 versus 13.5, p < 0.001). While those with intermittent hyperprolactinemia, bromocriptine and cabergoline bunches had non-critical distinction in prolactin level at 4 months after treatment (p>0.05). Treatment with Cabergoline had fundamentally lower prolactin level when contrasted with Bromocriptine bunch at about a month and 4 months.